Lexaria Bioscience (NASDAQ: LEXX, LEXXW) is a global innovator in drug delivery platforms. The company today issued information to its stakeholders as an aid to conveniently research and understand various non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. “Biotech companies with little to no revenue can still be worth billions,” Raphael Rottgen, CFA, FRM, was quoted in the press release. “While valuations can be extremely low or extremely high, there is often underlying logic in identifying risks and arriving at those valuations. Developing new drugs can have significant costs of over $1 billion and can take as long as 10 to 15 years to reach the market.”
The announcement clarifies that Lexaria’s DehydraTECH-CBD for hypertension program is currently operating within step three of five of the drug development process according to descriptions from the U.S. Food and Drug Administration (“FDA”). Under this step, various human studies seek to evidence both tolerability/safety as well as efficacy for intended purposes. Of the 5,000 – 10,000 compounds examined and tested in the discovery phase, not more than about 250 successfully complete the preclinical research step. Lexaria’s DehydraTECH-CBD is among those successes, having already reached and surpassed the preclinical research stage.
To view the full press release, visit https://ibn.fm/TKklc
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 26 patents granted and roughly 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment